Mechanism of action of non-coding RNA in sorafenib resistance in hepatocellular carcinoma

Guoxiang CHEN; Mo ZHOU; Sheng CHEN; Yuan WANG; Yuanlong ZHOU; Jihong YANG

doi:10.3969/j.issn.1001-5256.2021.03.040

Volume 37 Issue 3

Mar. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(3): 699-703

PDF( 2217 KB)

Mechanism of action of non-coding RNA in sorafenib resistance in hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2021.03.040

Department of Hepatobiliary Surgery, The Affiliated Hospital of Hebei University, Baoding, Hebei 071000, China

Received Date: 2020-08-28
Accepted Date: 2020-09-29
Published Date: 2021-03-20

Abstract

Abstract

Sorafenib, as the first-line treatment drug for advanced hepatocellular carcinoma (HCC), can effectively improve the prognosis of patients with HCC, but sorafenib resistance has become a major obstacle to the therapeutic outcome of HCC. Recent studies have shown that non-coding RNA plays a key role in sorafenib resistance in HCC. This article summarizes that non-coding RNA regulates the sensitivity of HCC to sorafenib by inducing the autophagy of hepatoma cells, promoting the proliferation of liver cancer stem cells, promoting the EMT process of hepatoma cells, inhibiting the apoptosis of hepatoma cells, and regulating the microenvironment of liver cancer tissue. It is pointed out that the molecular mechanism of non-coding RNA in regulating sorafenib resistance in HCC has potential clinical significance in overcoming sorafenib resistance in HCC.
- Carcinoma, Hepatocellular,
- RNA, Untranslated,
- Sorafenib,
- Drug Resistance, Neoplasm

FullText(HTML)

References(47)

References

[1]	HE YJ, ZHANG ZM, HE WM, et al. Epidemiologi-cal characteristics and prognosis of hepatocellular carcinoma: A single - center observational real - world cohort study of 1302 cases[J]. J Clin Hepatol, 2019, 35(5): 1002-1007. DOI: 10.3969/j.issn.1001-5256.2019.05.014 何雅婧, 张植明, 何伟猛, 等. 1302例单中心观察性肝细胞癌真实世界队列的流行病学特征与预后[J]. 临床肝胆病杂志, 2019, 35(5): 1002-1007. DOI: 10.3969/j.issn.1001-5256.2019.05.014
[2]	DING W, TAN Y, QIAN Y, et al. First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials[J]. PLoS One, 2020, 15(3): e0229492. DOI: 10.1371/journal.pone.0229492
[3]	AGIRRE E, EYRAS E. Databases and resources for human small non-coding RNAs[J]. Human Genomics, 2011, 5(3): 192-199. DOI: 10.1186/1479-7364-5-3-192
[4]	KOTAKE Y, TSURUDA T. Long noncoding RNA ANROC on the INK4 locus functions to suppress cell proliferation[J]. Cancer Genomics Proteomics, 2020, 17(4): 425-430. DOI: 10.21873/cgp.20201
[5]	TSANG WP, KWOK TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells[J]. Oncogene, 2007, 26(33): 4877-4881. DOI: 10.1038/sj.onc.1210266
[6]	ZHOU JJ, CHENG D, HE XY, et al. Knockdown of long non-coding RNA HOTAIR sensitizes hepatocellular carcinoma cell to cisplatin by suppressing the STAT3/ABCB1 signaling pathway[J]. Oncol Lett, 2017, 14(6): 7986-7992. http://europepmc.org/abstract/MED/29250186
[7]	SONNTAG R, GASSLER N, BANGEN JM, et al. Pro-apoptotic sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo[J]. Cell Death Dis, 2014, 5: e1030. DOI: 10.1038/cddis.2013.557
[8]	SAMARIN J, LAKETA V, MALZ M, et al. PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells[J]. Hepatology, 2016, 63(3): 813-826. DOI: 10.1002/hep.28357
[9]	WANG M, YU F, CHEN X, et al. The underlying mechanisms of Noncoding RNAs in the chemoresistance of hepatocellular carcinoma[J]. Mol Ther Nucleic Acids, 2020, 21: 13-27. DOI: 10.1016/j.omtn.2020.05.011
[10]	LAI HH, LI CW, HONG CC, et al. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma[J]. Mol Oncol, 2019, 13(4): 928-945. DOI: 10.1002/1878-0261.12449
[11]	FENG J, LI WD, TAN G. Recent advances of long non-coding RNA in tumor resistance by regulating autophagy[J]. Chin J Bases Clin Gen Surg, 2019, 26(7): 882-886. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL201907024.htm 冯京, 李伟东, 谭刚. 长链非编码RNA调控自噬以影响肿瘤耐药的研究进展[J]. 中国普外基础与临床杂志, 2019, 26(7): 882-886. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL201907024.htm
[12]	SHIMIZU S, TAKEHARA T, HIKITA H, et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma[J]. Int J Cancer, 2012, 131(3): 548-557. DOI: 10.1002/ijc.26374
[13]	CHEN CX, SUN LB, LI T, et al. Study on the molecular mechanism of LncRNA CRNDE up-regulating ATG4B and promoting autophagy of HCC cells[C]// The Chinese Society of Biochemistry and Molecular Biology, proceedings of the national academic conference and the 40th anniversary of the fouding of the society in 2019, 114. 陈岺曦, 孙梁博, 李涛, 等. LncRNA CRNDE上调ATG4B的分子机制及其促HCC细胞自噬的作用研究[C]//中国生物化学与分子生物学会, 中国生物化学与分子生物学会2019年全国学术会议暨学会成立四十周年论文集, 2019: 114.
[14]	JING Z, YE X, MA X, et al. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miRb via sponging EGR1 in hepatocellular carcinoma[J]. Cancer Medicine, 2020, 9(1): 4324-4338.
[15]	LI X, ZHOU Y, YANG L, et al. LncRNA NEAT1 promotes autophagy via regulating miR-204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma[J]. J Cell Physiol, 2020, 235(4): 3402-3413. DOI: 10.1002/jcp.29230
[16]	ZHANG K, CHEN J, ZHOU H, et al. PU. 1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib[J]. Cell Death Dis, 2018, 9(3): 312. DOI: 10.1038/s41419-018-0344-0
[17]	LI W, DONG X, HE C, et al. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells[J]. J Exp Clin Cancer Res, 2019, 38(1): 183. DOI: 10.1186/s13046-019-1177-0
[18]	HE C, DONG X, ZHAI B, et al. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway[J]. Oncotarget, 2015, 6(30): 28867-28881. DOI: 10.18632/oncotarget.4814
[19]	van ZIJL F, MALL S, MACHAT G, et al. A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression[J]. Mol Cancer Ther, 2011, 10(5): 850-860. DOI: 10.1158/1535-7163.MCT-10-0917
[20]	TAKAHASHI K, YAN IK, KOGURE T, et al. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer[J]. FEBS Open Bio, 2014, 4: 458-467. DOI: 10.1016/j.fob.2014.04.007
[21]	YANG C, CAI WC, DONG ZT, et al. lncARSR promotes liver cancer stem cells expansion via STAT3 pathway[J]. Gene, 2019, 687: 73-81. DOI: 10.1016/j.gene.2018.10.087
[22]	LU AQ, LV B, QIU F, et al. Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma[J]. Oncol Rep, 2017, 37(4): 2071-2078. DOI: 10.3892/or.2017.5498
[23]	RAN RZ, CHEN J, CUI LJ, et al. miR-194 inhibits liver cancer stem cell expansion by regulating RAC1 pathway[J]. Exp Cell Res, 2019, 378(1): 66-75. DOI: 10.1016/j.yexcr.2019.03.007
[24]	JIANG ZB, MA BQ, LIU SG, et al. miR-365 regulates liver cancer stem cells via RAC1 pathway[J]. Mol Carcinog, 2019, 58(1): 55-65. DOI: 10.1002/mc.22906
[25]	LI B, LIU D, YANG P, et al. miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway[J]. Gene, 2019, 707: 78-85. DOI: 10.1016/j.gene.2019.05.015
[26]	ZHANG PF, WANG F, WU J, et al. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma[J]. J Cell Physiol, 2019, 234(3): 2788-2794. DOI: 10.1002/jcp.27095
[27]	XIA H, OOI LL, HUI KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer[J]. Hepatology, 2013, 58(2): 629-641. DOI: 10.1002/hep.26369
[28]	JI C, LIU H, YIN Q, et al. miR-93 enhances hepatocellular carcinoma invasion and metastasis by EMT via targeting PDCD4[J]. Biotechnol Lett, 2017, 39(11): 1621-1629. DOI: 10.1007/s10529-017-2403-5
[29]	JIA H, YANG Q, WANG T, et al. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents[J]. Biochim Biophys Acta, 2016, 1860(7): 1417-1430. DOI: 10.1016/j.bbagen.2016.04.007
[30]	LIU K, LIU S, ZHANG W, et al. miR-222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma[J]. Int J Oncol, 2014, 45(4): 1537-1546. DOI: 10.3892/ijo.2014.2577
[31]	LIU K, LIU S, ZHANG W, et al. miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN[J]. Oncol Rep, 2015, 34(2): 1003-1010. DOI: 10.3892/or.2015.4030
[32]	FORNARI F, POLLUTRI D, PATRIZI C, et al. In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3-mediated apoptosis[J]. Clin Cancer Res, 2017, 23(14): 3953-3965. DOI: 10.1158/1078-0432.CCR-16-1464
[33]	CHEN S, XIA X. Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met[J]. J Cell Physiol, 2019, 234(9): 14999-15009. DOI: 10.1002/jcp.27567
[34]	AZUMI J, TSUBOTA T, SAKABE T, et al. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression[J]. Cancer Sci, 2016, 107(9): 1256-1262. DOI: 10.1111/cas.13006
[35]	YANG F, LI Q, GONG Z, et al. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to Sorafenib treatment[J]. Technol Cancer Res T, 2014, 13(1): 77-86. DOI: 10.7785/tcrt.2012.500364
[36]	XU Y, HUANG J, MA L, et al. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways[J]. Cancer Lett, 2016, 371(2): 171-181. DOI: 10.1016/j.canlet.2015.11.034
[37]	VAUPEL P. Prognostic potential of the pre-therapeutic tumor oxygenation status[J]. Adv Exp Med Biol, 2009, 645: 241-246. http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1007/978-0-387-85998-9_36
[38]	XU K, HE Z, CHEN M, et al. HIF-1α regulates cellular metabolism, and Imatinib resistance by targeting phosphogluconate dehydrogenase in gastrointestinal stromal tumors[J]. Cell Death Dis, 2020, 11(7): 586-590. DOI: 10.1038/s41419-020-02768-4
[39]	YIN X, LIAO Y, XIONG W, et al. Hypoxia-induced lncRNA ANRIL promotes cisplatin resistance in retinoblastoma cells through regulating ABCG2 expression[J]. Clin Exp Pharmacol Physiol, 2020, 47(6): 1049-1057. DOI: 10.1111/1440-1681.13279
[40]	SUN Q, ZHANG SY, ZHAO JF, et al. HIF-1α or HOTTIP/CTCF promotes head and neck squamous cell carcinoma progression and drug resistance by targeting HOXA9[J]. Mol Ther Nucleic Acids, 2020, 20: 164-175. DOI: 10.1016/j.omtn.2019.12.045
[41]	XU H, ZHAO L, FANG Q, et al. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α[J]. PLoS One, 2014, 9(12): e115565. DOI: 10.1371/journal.pone.0115565
[42]	TAKAHASHI K, YAN IK, WOOD J, et al. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy[J]. Mol Cancer Res, 2014, 12(10): 1377-1387. DOI: 10.1158/1541-7786.MCR-13-0636
[43]	KABIR TD, GANDA C, BROWN RM, et al. A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 216-231. DOI: 10.1002/hep.29478
[44]	LI M, SU Y, ZHANG F, et al. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy[J]. Acta Biomater, 2018, 75: 413-426. DOI: 10.1016/j.actbio.2018.05.049
[45]	ZHAO P, LI M, WANG Y, et al. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles[J]. Acta Biomater, 2018, 72: 248-255. DOI: 10.1016/j.actbio.2018.03.022
[46]	TANG S, TAN G, JIANG X, et al. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells[J]. Oncotarget, 2016, 7(45): 73257-73269. DOI: 10.18632/oncotarget.12304
[47]	CHEN Y, RAMJIAWAN RR, REIBERGER T, et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice[J]. Hepatology, 2015, 61(5): 1591-1602. DOI: 10.1002/hep.27665

Relative Articles

[1]	Baikun LIU, Zhiru WANG, Wenjing ZHAO. Effect of gallic acid in increasing the chemosensitivity of hepatocellular carcinoma HepG2 cells to sorafenib[J]. Journal of Clinical Hepatology, 2025, 41(2): 292-299. doi: 10.12449/JCH250215
[2]	Wei SUN, Xiaoyan DING, Jinglong CHEN. Efficacy and safety of anti-PD-1 monoclonal antibody combined with sorafenib or lenvatinib in treatment of patients with Child-Pugh class B unresectable hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(5): 975-981. doi: 10.12449/JCH240517
[3]	Xing WANG, Tao ZHANG. Value of alpha-fetoprotein response in evaluating the efficacy of sorafenib combined with camrelizumab in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(4): 843-849. doi: 10.3969/j.issn.1001-5256.2023.04.015
[4]	Dazhi LI, Junjie HUANG, Shusen ZHENG, Aibin ZHANG. Role of thioredoxin reductase 1 in multidrug resistance caused by reactive oxygen species-related cell apoptosis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(2): 372-380. doi: 10.3969/j.issn.1001-5256.2022.02.022
[5]	Xin CAI, Juanjuan CHEN, Dongling TANG, Pingan ZHANG. Role of circular RNA in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(3): 695-698. doi: 10.3969/j.issn.1001-5256.2021.03.039
[6]	Junmou GU, Libo WANG, Dejun ZENG, Qinwei LU, Kai DONG, Ruopeng LIANG, Weijie WANG, Rongtao ZHU, Yuling SUN. Differentially expressed mRNA involved in the resistance of liver cancer to anlotinib[J]. Journal of Clinical Hepatology, 2021, 37(2): 358-363. doi: 10.3969/j.issn.1001-5256.2021.02.022
[7]	Nannan QIAN, Lulu TANG, Taohua WEI, Yue YANG, Wenjie HAO, Wenming YANG. Role and mechanism of exosome non-coding RNA in liver fibrosis[J]. Journal of Clinical Hepatology, 2021, 37(10): 2429-2434. doi: 10.3969/j.issn.1001-5256.2021.10.036
[8]	Sun Bin, Yang XiaoZhen, Xie Fang, Pang LiJun, Chen DeXi, Wang YanJun. Effect of sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation on the survival of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(1): 104-108. doi: 10.3969/j.issn.1001-5256.2019.01.019
[9]	Chen Xiang, Wen DiGuang, You Yu, Gong JianPing. Role and mechanism of ferroptosis in treatment of liver cancer with sorafenib[J]. Journal of Clinical Hepatology, 2019, 35(10): 2316-2319. doi: 10.3969/j.issn.1001-5256.2019.10.040
[10]	Liao WeiRong, Gu Chao, Zhang DaWei. Clinical efficacy of sorafenib in treatment of primary hepatic carcinoma and its effects on serum VEGFR-2 and PLGF levels[J]. Journal of Clinical Hepatology, 2018, 34(6): 1220-1224. doi: 10.3969/j.issn.1001-5256.2018.06.018
[11]	Wu Lei, Wang Su. Research advances in transarterial chemoembolization combined with sorafenib in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(4): 867-871. doi: 10.3969/j.issn.1001-5256.2018.04.037
[12]	Gao BinCheng, Guo Hui, Sun Le, Zhou Jie, Jiang DongMei. Clinical effect of two targeted drugs in treatment of advanced hepatocellular carcinoma: A comparative analysis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1689-1692. doi: 10.3969/j.issn.1001-5256.2018.08.19
[13]	Zheng Kang, He MengGuo, Wang ZhiXiang. Therapeutic effect of transcatheter arterial chemoembolization combined with thalidomide or sorafenib in treatment of unresectable primary liver cancer: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(5): 899-903. doi: 10.3969/j.issn.1001-5256.2016.05.017
[14]	Zhang ChaoYa, Zhao XiangXuan, Lu ZaiMing, Guo QiYong. Research advances in sorafenib- induced apoptotic signaling pathways in liver cancer cells[J]. Journal of Clinical Hepatology, 2016, 32(4): 816-820. doi: 10.3969/j.issn.1001-5256.2016.04.048
[15]	Ma JingFan, Chen Gang, Liu Hong. TACE combined with sorafenib in treatment of advanced primary hepatocellular carcinoma: a report of one case achieving complete response[J]. Journal of Clinical Hepatology, 2016, 32(1): 152-154. doi: 10.3969/j.issn.1001-5256.2016.01.030
[16]	Chen Long, Liang Dong, Hou BenXin, Feng Jun, Lin YongPing, Lu ZhiCheng. Efficacy of sorafenib combined with capecitabine in Hui versus Han residents with advanced hepatocellular carcinoma in Sanya,Hainan,China: a comparative analysis[J]. Journal of Clinical Hepatology, 2015, 31(6): 895-898. doi: 10.3969/j.issn.1001-5256.2015.06.016
[17]	Zhang MingJuan, Liu Jia, Xiang XiaoXing, Wang Su. Research advances in sorafenib combined with orthotopic liver transplantation, radiofrequency ablation, and transarterial chemoembolization in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(8): 829-832. doi: 10.3969/j.issn.1001-5256.2014.08.037
[18]	Wan YunYan, Li Ling, Huang JunLi, Huang Rong, Ying KeMan, Chen Qiang, Luo Qi, Li WenGang. Effect of sorafenib and celecoxib combination therapy on proliferation of the human cholangiocarcinoma cell line SK-ChA-1 in vitro[J]. Journal of Clinical Hepatology, 2013, 29(1): 68-71.
[19]	Yang Jun, Meng QingHua, Yu HongWei. Sorafenib combined with thanscatheter artierial chemoembolzation in treatment of advanced hepatocellular carcinoma: Meta analysis[J]. Journal of Clinical Hepatology, 2013, 29(10): 764-768. doi: 10.3969/j.issn.1001-5256.2013.10.011
[20]	Sun JingJuan, Zhao HengJun, Li Wei, Miao FengHua, Wang NanYa. Clinical study of radiofrequency ablation therapy in combination with sorafenib for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2011, 27(10): 1093-1095+1098.

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	姜哲康，王高卿，高过，陆知非，华永飞. 索拉非尼在胆道恶性肿瘤中应用的研究进展. 中国医药导报. 2024(11): 193-195 .
2.	吴泽明，黄欣慧，彭琴，肖灵，黄梓源，林翊雅，谭宇蕙. 盐酸小檗胺通过调控自噬和PI3K/Akt/mTOR信号通路改善索拉非尼耐药的机制. 中国实验方剂学杂志. 2024(14): 78-88 .
3.	姚春，张广发，乐滢玉，毛德文，张荣臻，刘茵. 鞘磷脂酶在肝细胞癌中的作用. 临床肝胆病杂志. 2022(02): 461-465 . 本站查看
4.	李健宜，佟丹丹，林俊生. 恶性肿瘤饥饿疗法研究现状. 浙江大学学报(医学版). 2022(02): 241-250 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (1056) PDF downloads(49)

Mechanism of action of non-coding RNA in sorafenib resistance in hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2021.03.040